Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Armata Pharmaceuticals (ARMP) is set to announce its quarterly earnings before the market opens on Tuesday, August 12th, with expected losses of ($0.39) per share and revenue of $1.38 million.
• The company's stock is currently down 3.1%, trading at $2.63, with a market cap of $95 million and a price-to-earnings ratio of -3.16.
• HC Wainwright has raised Armata Pharmaceuticals' price target from $7.00 to $9.00 and maintains a "buy" rating, providing optimism for investors.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, August 12th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.39) per share and revenue of $1.38 million for the quarter.

Armata Pharmaceuticals Stock Up 2.1%

Shares of NYSEAMERICAN:ARMP traded up $0.05 during trading on Friday, hitting $2.41. 4,667 shares of the company were exchanged, compared to its average volume of 12,132. The stock has a market capitalization of $87.22 million, a PE ratio of -2.90 and a beta of 0.99. Armata Pharmaceuticals has a 12-month low of $0.90 and a 12-month high of $2.96. The company has a 50 day moving average of $2.17.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their price objective on shares of Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Monday, May 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.